The new syndicated study, which adds to Ipsos’ global therapy monitor portfolio, will combine patient data with the perceptions of doctors treating the condition.

The study will measure market share, key drivers for treatment choice and patients’ progression through the patient pathway.

Subscribers will be able to identify the opportunity for novel agents and which patients are more likely to be moved on to novel therapies, the attributes doctors rate as the most important in prescribing, and how specific products perform.

Ipsos plans to extend the monitor to other markets.

Dr Sabina Heinz, director of real world evidence in global diseases at Ipsos Healthcare said: “Ipsos’ therapy monitor will be there to monitor the uptake of new biologics in the [severe asthma] market. This will give our clients the real world evidence they need to ascertain the impact of their drugs, both on the market and on the patient population.”